10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
April 23, 2024 16:42 ET
|
10X Capital Venture Acquisition Corp. III
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
January 31, 2024 17:16 ET
|
10X Capital Venture Acquisition Corp. III
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB, VCXB.U, VCXB WS) (“10X III”), announced today that NYSE Regulation (“NYSER”), by...
10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
January 08, 2024 06:00 ET
|
10X Capital Venture Acquisition Corp. III
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American:VCXB), a publicly traded special purpose acquisition company,...
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
November 28, 2023 16:10 ET
|
10X Capital Venture Acquisition Corp. III
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by letter...
10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
October 04, 2023 18:07 ET
|
10X Capital Venture Acquisition Corp. III
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its Class A...
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
August 09, 2023 21:07 ET
|
10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those...
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
August 09, 2023 19:02 ET
|
10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those...
SPARKS ENERGY, A LEADER IN POWER INFRASTRUCTURE SERVICES AND RESTORATION, TO LIST ON NEW YORK STOCK EXCHANGE THROUGH MERGER WITH 10X CAPITAL VENTURE ACQUISITION CORP. III
December 21, 2022 07:00 ET
|
10X Capital Venture Acquisition Corp. III
Sparks Energy, Inc. (“Sparks”), a power infrastructure services firm and a leader in power restoration management, has entered into a merger agreement with 10X Capital Venture Acquisition Corp. III...
10X Capital Venture Acquisition Corp. III Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing March 4, 2022
March 01, 2022 16:05 ET
|
10X Capital Venture Acquisition Corp. III
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) (the “Company”) today announced that, commencing March 4, 2022, holders of the units sold in the...
10X Capital Venture Acquisition Corp. III Announces Closing of Upsized $300 Million Initial Public Offering
January 14, 2022 15:18 ET
|
10X Capital Venture Acquisition Corp. III
New York, NY , Jan. 14, 2022 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) (the “Company”) today announced that it closed its initial public offering of 30,000,000...